Sep. 15 at 5:22 PM
$BOLT Only green ticker on my list today. Data is in ~2 months. This reminds me of Harpoon Therapeutics from a few years ago (HARP).
-HARP hit an all time low of ~
$1.00/share mid 2023 (22m market cap)
-HARP had Phase 1/2 interim data due in October 2023 (BOLT Phase 1/2 due this Nov 2026)
-HARP ran from
$1 -
$4 pre-data (Aug to October 2023)
-Phase 1/2 interim data came back positive late October 2023
-Financing of 150M came days later, stock went to
$11/share
-HARP got bought out 3 months later Jan 2024 by Merck for
$28 (~600m mc)
The parallels between the two are quite striking when you look into the details. I think this is the plan BOLT has for positive BDC-4182 data. If data is bad, then it's likely a reverse merger situation, but at a current 7.5m market cap it seems the downside is limited either way imo.
